In France, vaccination against seasonal flu is recommended each year for people aged 65 and over, and for people at risk of severe or complicated flu (i.e. those suffering from chronic illness(es), obese, staying in a follow-up care establishment or in a medico-social establishment regardless of their age, pregnant women, those around infants under 6 months presenting serious risk factors) and caregivers.
In February 2024, the World Health Organization (WHO) recommended the removal of the B/Yamagata lineage influenza strain from the composition of influenza vaccines, due to its non-detection since March 2020. In March 2024, the European Medicines Agency (EMA) wanted this transition to trivalent formulations to be completed for the 2025/2026 season.
HAS today publishes the opinion concerning the transition of the INFLUVAC influenza vaccine from its quadrivalent form to a trivalent form, in the vaccination strategy against seasonal influenza.
- Recommendation
- Europe
- France
- Influenza
